CT-011 met the primary endpoint of improved progression-free survival (PFS) in patients with Diffuse Large B Cell Lymphoma (DLBCL) following autologous stem cell transplantation.
The company says statistically significant results have also been achieved in the secondary endpoint of Overall Survival (OS).
Preliminary analyses indicate that 70% of the patients treated with CT-011 were progression-free at the end of the follow-up period, as compared to only 47% in the historical control.
Teva holds about 33% of CureTech and has the option to buy all shares.
- Follow Ynetnews on Facebook